Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 ROCKVILLE, Md., June 29, 2021 ...

Phase 1 Clinical Program Intended to Support Development of SYN-020 in Multiple Indications, Including Treatment of Celiac Disease, Non-Alcoholic Fatty Liver Disease and Age-Related Metabolic and ...

Good afternoon and welcome to the Synthetic Biologics' 2020 First Quarter Investor Conference Call. At this time, I would like to turn the call over to Vincent Perrone, Director, Corporate ...

Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with ...

Ramsey, NJ, May 28, 2020 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta), a leader in industrial and commercial printing and packaging solutions, today announced ...

Greetings and welcome to the Synthetic Biologics Fourth Quarter and Full Year 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...